ETElizabeth M. Tunbridge

Elizabeth M. Tunbridge

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Elizabeth M. Tunbridge has a total of 331 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    On Translational Misalignment in Reinforcement and Motivation Research

    by Dennis Hernaus, Geor Bakker, Gerard R. Dawson, Oliver Grimm, Catherine J. Harmer, Mitul A. Mehta, Jonathan P. Roiser, James A. Waltz, Nic van der Wee, Elizabeth M. Tunbridge

  • Open Access

    The psychiatric risk gene CACNA1C encodes distinct full-length isoforms in human brain, heart and aorta

    by Nicola AL Hall, Arne W. Mould, Isar Nassiri, Sofia Kudasheva, David J. Wright, Li Chen, Osama A. Arshad, Ran Tao, Joel E. Kleinman, Daniel R. Weinberger, et al.

    CACNA1C is a risk gene for multiple psychiatric disorders and the Ca V 1.2 protein it encodes is a potential target for their treatment. It is known that alternative start exon usage and splicing of CACNA1C RNA results in multiple transcript isoforms. However, the identity of full-length isoforms, and their relative abundance between tissues, remains unknown. Such information is important for understanding the molecular mechanisms of illness associations and to advance the potential for Ca V 1.2 isoform-selective drugs. In this study we compared full-length isoforms expressed in human brain with those expressed in heart and aorta using PCR-targeted long-read nanopore amplicon sequencing. We also performed 5’-RACE to profile which CACNA1C transcription start exons are used. CACNA1C RNA splicing revealed distinct tissue-enriched isoforms in brain, heart and aorta, with the results corroborated by publicly available short-read RNA-seq data. For example, splicing of mutually exclusive exons 21 and 22 differentiated isoforms expressed in the brain from those in the heart and aorta. 5’-RACE identified a novel start exon, exon 1d, which was detected in brain and aorta but not heart, and which predicts channels with a truncated N-terminus. The full-length isoforms identified here, from both the previously known start exons and the novel start exon, are likely to impact on the function and the pharmacology of the encoded Ca V 1.2 channel. Identification of brain-enriched isoforms provides the possibility of designing drugs preferentially targeting Ca V 1.2 for psychiatric indications.


  • Open Access

    On Translational Misalignment in Reinforcement and Motivation Research

    by Dennis Hernaus, Geor Bakker, Gerard R. Dawson, Oliver Grimm, Catherine Harmer, Mitul Mehta, Jonathan Paul Roiser, James Waltz, Nic van der Wee, Elizabeth Tunbridge

    Despite major advances in computational psychiatry, neuroimaging, and preclinical neuroscience, progress in the development of effective treatments for motivational dysfunction has remained challenging. Here, we argue that part of this challenge arises because complex real-life motivational phenomena are progressively transformed when they move across the translational research spectrum.The aim of this brief review is to highlight three related gaps that contribute to this form of “translational misalignment”. First, experimental paradigms simplify and compress ecological human motivational experiences into tractable (sub-)constructs. Second, clinical manifestations of motivational dysfunction are heterogeneous, measured and operationalized inconsistently across research fields, and only partially align with metrics from experimental paradigms. Third, preclinical animal models rely on behavioral inference, aim for mechanistic optimization, and often use extreme and/or constrained phenotypes that may incompletely correspond to motivational dysfunction in humans.We conclude with a discussion on how more iterative and human-grounded forms of back-translation could help preserve alignment between lived motivational phenomena, laboratory measures, clinical symptoms, and preclinical models. These approaches may ultimately improve translational validity in reinforcement- and motivation-focused neuropsychopharmacology research and aide the much-needed delivery of new therapeutics.

  • Open Access

    The therapeutic potential of COMT inhibition: cognition and beyond

    by Elizabeth M. Tunbridge, Gregory V. Carr, Daniel R. Weinberger

    The catechol-O-methyltransferase (COMT) enzyme regulates dopamine signaling in the prefrontal cortex (PFC). Given the role of PFC dopamine in the regulation of different aspects of executive function, COMT has emerged as a potential modulator of such behaviours. Here, we review the evidence linking COMT with executive function, with a particular focus on human studies using the brain penetrant COMT inhibitor tolcapone. Although small in scale, multiple studies demonstrate improvements in working memory after COMT inhibition in a manner dependent on baseline PFC dopamine signaling, consistent with the well-established inverted-U shaped relationship between PFC dopamine signaling and working memory performance. However, the effects of COMT inhibition extend not only to other cognitive domains but also to other aspects of executive control, notably including the regulation of impulsive or risky behaviours. Findings from rodents are broadly consistent with the human data: animals with lower COMT activity, mediated either genetically or pharmacologically, also show relatively better cognitive performance and reduced impulsive behaviours, compared to wild type/vehicle-treated animals. Taken together, these data are consistent with a model whereby COMT regulates PFC dopamine signaling to modulate top-down control over multiple aspects of behaviour. These findings suggest COMT inhibition as an attractive therapeutic approach in individuals with neuropsychiatric disorders associated with aspects of executive dysfunction.

  • Top Cited Papers
    Open Access

    Biomarker innovations in precision psychiatry diagnostics and treatment strategies

    by Martien J.H. Kas, Kim Q. Do, Michael S. Sand, Rouba Kozak, Elizabeth M. Tunbridge, Maria A. Oquendo, Carol Tamminga, Nikolaos Koutsouleris, Gitte Moos Knudsen, Brenda W.J.H. Penninx, et al.


  • Open Access

    Timothy Syndrome and CACNA1C-Related Disorder: First International Language and Management Guidelines Consensus Statement

    by Jack F. G. Underwood, Katherine W. Timothy, Holly Tyroll, Rebecca J. Levy, Ivy E. Dick, Geoffrey S. Pitt, Elizabeth M. Tunbridge, Anwar Baban, Gemma Wilkinson, Nicola A. L. Hall, et al.

    Timothy Syndrome is a multisystemic genetic disorder, classically characterised by prolonged QT interval and subsequent cardiac arrhythmias, neurodevelopmental disorders including developmental delay and autism, and syndactyly or hip dysplasia. It is caused by variants in the CACNA1C gene, which encodes the widely expressed Ca v 1.2 voltage-gated calcium channel. Since it’s characterisation in 2004, the spread of variants in CACNA1C associated with Timothy Syndrome has expanded. With advances in sequencing and the inclusion of CACNA1C in genomic screening, further variants have been identified presenting with incomplete features of Timothy Syndrome or further aligned phenotypes which are inconsistent with the original description. In the absence of a formal nomenclature, these presentations have been reported in a proliferation of ill-defined terms, e.g. Atypical Timothy Syndrome. At the same time, advances in knowledge and therapeutics have improved morbidity and life expectancy for these individuals when appropriately identified and managed. Here, we present guidelines for the diagnosis of individuals presenting with variants in CACNA1C , developed by an international panel of experts through Delphi consensus with the involvement of the CACNA1C community. We formalise the language around syndromic presentations linked to CACNA1C variants, reassert and demarcate the classical Timothy Syndrome phenotype, and define a new syndrome, CACNA1C-Related Disorder. Finally, we present minimum expected standards of clinical care for individuals with CACNA1C-Related Disorder or Timothy Syndrome, with implications for long-term management and improved outcomes for affected individuals.

  • Open Access

    Human-specific tandem repeat in CACNA1C modulates responses to neuronal stimulation

    by Janet H.T. Song, Fikri Birey, Tzu-Chiao Hung, Nicola A.L. Hall, Catherine A. Guenther, Xiaoyu Chen, Ibrahim F. Alkuraya, Elizabeth M. Tunbridge, Wilfried Haerty, Sergiu P. Pasca, et al.

    The recent development of long-read sequencing has made it possible to catalog variable number tandem repeats (VNTRs) in the human genome. However, little is known about their functional consequences. Here, we characterized the effect of TRACT, a VNTR that is unique to humans and that has sequence variants linked to risk for bipolar disorder and schizophrenia. By adding or removing this VNTR in both mouse models and human neural organoids, we find that TRACT, which is intronic to the L-type voltage-gated calcium channel gene CACNA1C , increases intracellular calcium after neuronal stimulation and leads to widespread changes in activity-dependent transcription programs in neurons. TRACT-dependent changes are enriched for genes associated with synapse formation and plasticity, and partially recapitulate evolutionary changes in activity-dependent transcription between species. These findings demonstrate that a single, human-specific, non-coding element can strongly affect the neuronal response to stimulation, and motivate the study of VNTRs as a genetic source of phenotypic variation in both evolution and disease.


  • Open Access

    Temporal Dynamics of Subtle Cognitive Change: Validation of a User-Friendly Multidomain Digital Assessment Using an Alcohol Challenge

    by John Frederick Dyer, Florentine Marie Barbey, Ayan Ghoshal, Ann Marie Hake, Bryan J Hansen, Nurul Islam, Judith Jaeger, Rouba Kozak, Hugh Marston, Mark Moss, et al.

    Background: Clinical trials in neurological and psychiatric indications are hampered by poor measurement fidelity in currently used “standardized” rating scales. Digital, repeatable tests that can be remotely administered offer a more fine-grained understanding of the patient’s clinical trajectory. Several such tools are being developed, but only a few have been validated in terms of their ability to discern and describe change over time—a critical element of clinical trials. Objective: Four cognitive tasks from a digital battery (delivered via tablet) are administered at high frequency following an alcohol challenge to assess sensitivity to change. The tasks are novel, repeatable, and self-administered implementations of classic neurobehavioral paradigms. Methods: Thirty healthy younger adults were assessed on 2 separate days, once under the influence of alcohol and once under a placebo, with order counterbalanced. Each day included 8 assessments. The tasks comprised novel, engaging implementations of the Digit Symbol Substitution Task (DSST), reaction time, N-back working memory, and visual associative/episodic memory, and were compared with benchmark measures. In-laboratory assessments were preceded by massed practice (3 sessions), and blood alcohol concentration was monitored throughout using a breathalyzer and a Visual Analog Scale. Results: Alcohol-related impairment was observed across multiple measures, followed by a return to baseline as blood alcohol concentration declined. A slight practice effect was noted between the first and second sessions for the digital DSST, along with a longer-term effect across the 2 days. Moderate to strong correlations between digital and benchmark measures were observed at peak intoxication. Conclusions: Under alcohol challenge, this battery, along with benchmark standardized tests, demonstrates sensitivity to subtle changes in cognitive performance over time. Practice effects are minimal within this condensed protocol. Patient-friendly, repeatable tests administered via a digital platform, such as those in the current battery, warrant further investigation in the context of remote clinical studies that require methodological approaches capable of discerning and describing small changes over time. The availability of validated single tests or test batteries as sensitive tools that can be easily and frequently administered (eg, daily) would address a critical gap: the lack of descriptors with sufficient sensitivity, specificity, and reliability to detect cognitive changes over time in clinical trials of new therapies for neurological and psychiatric conditions.

  • Open Access

    Temporal Dynamics of Subtle Cognitive Change: Validation of a User-Friendly Multidomain Digital Assessment Using an Alcohol Challenge (Preprint)

    by John Frederick Dyer, Florentine Marie Barbey, Ayan Ghoshal, Ann Marie Hake, Bryan J Hansen, Nurul Islam, Judith Jaeger, Rouba Kozak, Hugh Marston, Mark Moss, et al.

    BACKGROUND Clinical trials in neurological and psychiatric indications are hampered by poor measurement fidelity in currently used “standardized” rating scales. Digital, repeatable tests that can be remotely administered offer a more fine-grained understanding of the patient’s clinical trajectory. Several such tools are being developed, but only a few have been validated in terms of their ability to discern and describe change over time—a critical element of clinical trials. OBJECTIVE Four cognitive tasks from a digital battery (delivered via tablet) are administered at high frequency following an alcohol challenge to assess sensitivity to change. The tasks are novel, repeatable, and self-administered implementations of classic neurobehavioral paradigms. METHODS Thirty healthy younger adults were assessed on 2 separate days, once under the influence of alcohol and once under a placebo, with order counterbalanced. Each day included 8 assessments. The tasks comprised novel, engaging implementations of the Digit Symbol Substitution Task (DSST), reaction time, N-back working memory, and visual associative/episodic memory, and were compared with benchmark measures. In-laboratory assessments were preceded by massed practice (3 sessions), and blood alcohol concentration was monitored throughout using a breathalyzer and a Visual Analog Scale. RESULTS Alcohol-related impairment was observed across multiple measures, followed by a return to baseline as blood alcohol concentration declined. A slight practice effect was noted between the first and second sessions for the digital DSST, along with a longer-term effect across the 2 days. Moderate to strong correlations between digital and benchmark measures were observed at peak intoxication. CONCLUSIONS Under alcohol challenge, this battery, along with benchmark standardized tests, demonstrates sensitivity to subtle changes in cognitive performance over time. Practice effects are minimal within this condensed protocol. Patient-friendly, repeatable tests administered via a digital platform, such as those in the current battery, warrant further investigation in the context of remote clinical studies that require methodological approaches capable of discerning and describing small changes over time. The availability of validated single tests or test batteries as sensitive tools that can be easily and frequently administered (eg, daily) would address a critical gap: the lack of descriptors with sufficient sensitivity, specificity, and reliability to detect cognitive changes over time in clinical trials of new therapies for neurological and psychiatric conditions.